| Primary |
| Atrial Fibrillation |
29.2% |
| Drug Use For Unknown Indication |
19.8% |
| Product Used For Unknown Indication |
13.1% |
| Deep Vein Thrombosis |
7.6% |
| Pulmonary Embolism |
6.6% |
| Anticoagulant Therapy |
6.2% |
| Thrombosis Prophylaxis |
2.9% |
| Cerebrovascular Accident |
1.9% |
| Hypertension |
1.9% |
| Pain |
1.8% |
| Aortic Valve Replacement |
1.1% |
| Coronary Artery Disease |
1.0% |
| Cardiac Failure Congestive |
0.9% |
| Mitral Valve Replacement |
0.9% |
| Heart Valve Replacement |
0.9% |
| Prophylaxis |
0.9% |
| Rheumatoid Arthritis |
0.9% |
| Thrombosis |
0.9% |
| Urinary Tract Infection |
0.9% |
| Cardiac Failure |
0.7% |
|
| International Normalised Ratio Increased |
39.1% |
| Subdural Haematoma |
6.2% |
| Drug Interaction |
5.9% |
| Haemorrhage |
5.9% |
| Melaena |
3.9% |
| Gastric Haemorrhage |
3.6% |
| International Normalised Ratio Abnormal |
3.6% |
| Gastrointestinal Haemorrhage |
3.4% |
| Vomiting |
3.3% |
| International Normalised Ratio Decreased |
3.1% |
| Rectal Haemorrhage |
3.1% |
| Urinary Tract Infection |
2.8% |
| Haemoglobin Decreased |
2.5% |
| Upper Gastrointestinal Haemorrhage |
2.3% |
| Cerebral Haemorrhage |
2.0% |
| Haemorrhage Intracranial |
2.0% |
| Weight Decreased |
2.0% |
| Renal Tubular Necrosis |
1.9% |
| Subdural Haemorrhage |
1.9% |
| Product Substitution Issue |
1.7% |
|
| Secondary |
| Product Used For Unknown Indication |
27.1% |
| Atrial Fibrillation |
13.5% |
| Drug Use For Unknown Indication |
13.1% |
| Hypertension |
6.2% |
| Deep Vein Thrombosis |
5.3% |
| Anticoagulant Therapy |
5.2% |
| Thrombosis Prophylaxis |
4.0% |
| Pulmonary Embolism |
3.7% |
| Cardiac Failure |
3.2% |
| Cardiac Failure Chronic |
2.8% |
| Prophylaxis |
2.5% |
| Depression |
2.1% |
| Pain |
1.9% |
| Diabetes Mellitus |
1.7% |
| Pulmonary Arterial Hypertension |
1.5% |
| Cardiac Failure Congestive |
1.3% |
| Cerebral Artery Embolism |
1.3% |
| Pulmonary Hypertension |
1.3% |
| Cerebrovascular Accident Prophylaxis |
1.2% |
| Constipation |
1.2% |
|
| International Normalised Ratio Increased |
33.3% |
| Completed Suicide |
6.1% |
| Toxicity To Various Agents |
4.8% |
| Death |
4.6% |
| Vomiting |
4.3% |
| Urinary Tract Infection |
4.1% |
| Haemorrhage |
3.9% |
| Thrombocytopenia |
3.9% |
| Drug Interaction |
3.7% |
| International Normalised Ratio Decreased |
3.0% |
| Subdural Haematoma |
3.0% |
| Weight Decreased |
3.0% |
| Drug Resistance |
2.8% |
| Gastrointestinal Haemorrhage |
2.8% |
| Overdose |
2.8% |
| Prothrombin Time Prolonged |
2.8% |
| Tachycardia |
2.8% |
| Thrombosis |
2.8% |
| Hepatitis Acute |
2.6% |
| Rash |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
36.2% |
| Drug Use For Unknown Indication |
13.5% |
| Hypertension |
8.0% |
| Atrial Fibrillation |
7.7% |
| Pain |
3.8% |
| Prophylaxis |
3.4% |
| Pulmonary Arterial Hypertension |
2.8% |
| Rheumatoid Arthritis |
2.7% |
| Diabetes Mellitus |
2.6% |
| Cardiac Failure |
2.4% |
| Blood Cholesterol Increased |
2.0% |
| Multiple Myeloma |
2.0% |
| Anticoagulant Therapy |
1.9% |
| Pulmonary Hypertension |
1.8% |
| Cardiac Disorder |
1.7% |
| Constipation |
1.6% |
| Depression |
1.6% |
| Chronic Obstructive Pulmonary Disease |
1.5% |
| Thrombosis Prophylaxis |
1.5% |
| Osteoporosis |
1.5% |
|
| Vomiting |
11.1% |
| Weight Decreased |
9.2% |
| Death |
6.9% |
| Pneumonia |
6.1% |
| International Normalised Ratio Increased |
5.3% |
| Weight Increased |
5.2% |
| Drug Ineffective |
5.1% |
| Pulmonary Embolism |
5.0% |
| Thrombosis |
4.8% |
| Renal Failure Acute |
4.7% |
| Oedema Peripheral |
4.2% |
| Urinary Tract Infection |
4.1% |
| Dyspnoea |
4.0% |
| Pyrexia |
3.6% |
| Rhabdomyolysis |
3.6% |
| Vision Blurred |
3.5% |
| Pain In Extremity |
3.5% |
| Renal Impairment |
3.4% |
| Interstitial Lung Disease |
3.3% |
| Tremor |
3.2% |
|
| Interacting |
| Cerebrovascular Accident |
27.3% |
| Atrial Fibrillation |
12.9% |
| Product Used For Unknown Indication |
9.7% |
| Castleman's Disease |
7.3% |
| Heart Valve Replacement |
6.3% |
| Drug Use For Unknown Indication |
6.2% |
| Deep Vein Thrombosis |
3.7% |
| Prophylaxis |
2.5% |
| Candida Infection |
2.4% |
| Cardiac Failure Chronic |
2.3% |
| Hypertension |
2.3% |
| Psoriasis |
2.3% |
| Pain |
2.2% |
| Pulmonary Embolism |
2.2% |
| Cardiac Failure |
2.2% |
| Urinary Tract Infection |
1.9% |
| Anticoagulant Therapy |
1.9% |
| Ill-defined Disorder |
1.7% |
| Staphylococcal Infection |
1.6% |
| Thrombosis Prophylaxis |
1.2% |
|
| International Normalised Ratio Increased |
45.1% |
| Drug Interaction |
17.1% |
| International Normalised Ratio Decreased |
4.9% |
| Pulmonary Embolism |
3.5% |
| Inhibitory Drug Interaction |
2.9% |
| International Normalised Ratio Abnormal |
2.6% |
| Thrombosis |
2.6% |
| Syncope |
2.3% |
| Haemorrhage |
2.0% |
| Off Label Use |
2.0% |
| Haematoma |
1.7% |
| International Normalised Ratio Fluctuation |
1.7% |
| Malaise |
1.7% |
| Gastrointestinal Haemorrhage |
1.4% |
| Labelled Drug-drug Interaction Medication Error |
1.4% |
| Post Procedural Haemorrhage |
1.4% |
| Prothrombin Time Prolonged |
1.4% |
| Therapeutic Response Unexpected |
1.4% |
| Vomiting |
1.4% |
| Rhabdomyolysis |
1.2% |
|
